Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap Up – What’s Next?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $20.58, but opened at $22.32. Catalyst Pharmaceuticals shares last traded at $22.61, with a volume of 323,057 shares.

Analyst Ratings Changes

CPRX has been the subject of several analyst reports. Stephens restated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday. Robert W. Baird started coverage on Catalyst Pharmaceuticals in a research note on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday. Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Price Performance

The firm has a market cap of $2.73 billion, a PE ratio of 19.40, a PEG ratio of 3.31 and a beta of 0.80. The business has a 50-day moving average price of $22.24 and a two-hundred day moving average price of $21.43.

Insider Activity

In other news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $27,000. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $29,000. Farther Finance Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,495 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $65,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.